342 related articles for article (PubMed ID: 33423164)
1. An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression.
Khan AA; Liu X; Yan X; Tahir M; Ali S; Huang H
Cancer Metastasis Rev; 2021 Mar; 40(1):245-272. PubMed ID: 33423164
[TBL] [Abstract][Full Text] [Related]
2. Selective epigenetic alterations in RNF43 in pancreatic exocrine cells from high-fat-diet-induced obese mice; implications for pancreatic cancer.
Araki T; Miwa N
BMC Res Notes; 2024 Apr; 17(1):106. PubMed ID: 38622664
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer.
Rah B; Banday MA; Bhat GR; Shah OJ; Jeelani H; Kawoosa F; Yousuf T; Afroze D
World J Gastroenterol; 2021 Sep; 27(36):6093-6109. PubMed ID: 34629822
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.
Mishra NK; Guda C
Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.
Suehiro Y; Wong CW; Chirieac LR; Kondo Y; Shen L; Webb CR; Chan YW; Chan AS; Chan TL; Wu TT; Rashid A; Hamanaka Y; Hinoda Y; Shannon RL; Wang X; Morris J; Issa JP; Yuen ST; Leung SY; Hamilton SR
Clin Cancer Res; 2008 May; 14(9):2560-9. PubMed ID: 18451217
[TBL] [Abstract][Full Text] [Related]
6. Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy.
Ganji C; Farran B
Drug Discov Today; 2022 May; 27(5):1404-1410. PubMed ID: 34952224
[TBL] [Abstract][Full Text] [Related]
7. [Genetic aspects of pancreatic cancer].
Grigor'eva IN; Efimova OV; Suvorova TS; Tov NL
Eksp Klin Gastroenterol; 2014; (10):70-6. PubMed ID: 25911935
[TBL] [Abstract][Full Text] [Related]
8. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking.
Jiao L; Zhu J; Hassan MM; Evans DB; Abbruzzese JL; Li D
Pancreas; 2007 Jan; 34(1):55-62. PubMed ID: 17198183
[TBL] [Abstract][Full Text] [Related]
9. Genomic sequencing of key genes in mouse pancreatic cancer cells.
Wang Y; Zhang Y; Yang J; Ni X; Liu S; Li Z; Hodges SE; Fisher WE; Brunicardi FC; Gibbs RA; Gingras MC; Li M
Curr Mol Med; 2012 Mar; 12(3):331-41. PubMed ID: 22208613
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of rapid on-site evaluation specimens from endoscopic ultrasound-guided fine-needle aspiration for cancer gene panel testing: A retrospective study.
Ishizawa T; Makino N; Matsuda A; Kakizaki Y; Kobayashi T; Ikeda C; Sugahara S; Tsunoda M; Ueno Y
PLoS One; 2020; 15(1):e0228565. PubMed ID: 31999789
[TBL] [Abstract][Full Text] [Related]
11. Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma.
Xu R; Xu Q; Huang G; Yin X; Zhu J; Peng Y; Song J
Biomed Res Int; 2019; 2019():9379864. PubMed ID: 31956659
[TBL] [Abstract][Full Text] [Related]
12. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
13. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.
Khan MA; Azim S; Zubair H; Bhardwaj A; Patel GK; Khushman M; Singh S; Singh AP
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28383487
[TBL] [Abstract][Full Text] [Related]
14. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation frequency of TNFRSF10C promoter in pancreatic cancer cell lines.
Cai HH; Sun YM; Miao Y; Gao WT; Peng Q; Yao J; Zhao HL
Hepatobiliary Pancreat Dis Int; 2011 Feb; 10(1):95-100. PubMed ID: 21269942
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.
Rachagani S; Macha MA; Heimann N; Seshacharyulu P; Haridas D; Chugh S; Batra SK
Adv Drug Deliv Rev; 2015 Jan; 81():16-33. PubMed ID: 25453266
[TBL] [Abstract][Full Text] [Related]
17. Genetic and epigenetic alterations of familial pancreatic cancers.
Brune K; Hong SM; Li A; Yachida S; Abe T; Griffith M; Yang D; Omura N; Eshleman J; Canto M; Schulick R; Klein AP; Hruban RH; Iacobuzio-Donohue C; Goggins M
Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3536-42. PubMed ID: 19064568
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathology of pancreatic cancer.
Saiki Y; Horii A
Pathol Int; 2014 Jan; 64(1):10-9. PubMed ID: 24471965
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability.
Jäkel C; Bergmann F; Toth R; Assenov Y; van der Duin D; Strobel O; Hank T; Klöppel G; Dorrell C; Grompe M; Moss J; Dor Y; Schirmacher P; Plass C; Popanda O; Schmezer P
Nat Commun; 2017 Nov; 8(1):1323. PubMed ID: 29109526
[TBL] [Abstract][Full Text] [Related]
20. Surveillance for familial pancreatic cancer.
de Vos tot Nederveen Cappel WH; Lagendijk MA; Lamers CB; Morreau H; Vasen HF
Scand J Gastroenterol Suppl; 2003; (239):94-9. PubMed ID: 14743890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
